Description du projet
Des protéines de la membrane de la coquille d’œuf utilisées pour la cicatrisation des plaies chroniques
Les plaies chroniques comme l’ulcère de jambe, l’escarre et l’ulcère du pied diabétique sont des plaies qui ne guérissent pas en moins de trois mois ou guérissent sans restauration de l’intégrité fonctionnelle. Outre un temps de récupération s’étalant sur des années ou des décennies, les patients souffrent autant d’une douleur intense que de détresse émotionnelle et de mobilité limitée. Ce projet financé par l’UE travaillera sur la validation clinique et la production commerciale de DermaRep, un pansement innovant récemment développé par la société Biovotec. Isolé de la membrane de la coquille d’œuf et facilement disponible, ce produit révolutionnaire pourrait devenir une nouvelle référence dans la cicatrisation des plaies tout en réduisant le coût énorme du traitement des plaies chroniques.
Objectif
A chronic wound (such as Leg Ulcer (LU), Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) can be defined as one that has failed to proceed through an orderly and timely reparative process to produce anatomic and functional integrity within a period of 3 months or that has proceeded through the repair process without establishing a sustained and anatomic and functional result. Chronic wounds may require several years to heal, and some remain unhealed for decades. During this time, patients can experience severe pain, significant emotional and physical distress, reduced mobility and social isolation.
LU, PU and DFU are a major healthcare cost for all developed countries. The main driver for growth in cost is the treatment of chronic and complex wounds in the aging population, complicated by the increase in diabetes and other metabolic disorders. LUs account for $50Bn of global wound care burden in 2015 and are to reach $53Bn in 2020. DFUs account for $52Bn – and are to reach $56Bn by 2020. Further, PUs account for $41Bn of global wound care burden in 2015 – and are to reach $47Bn by 2020.
We have developed an innovative wound dressing, DermaRep™, that is based on biomaterial derived from Eggshell Membrane (ESM) – a by-product readily available in the egg industry. The purified form of ESM is called Purified Eggshell Membrane Protein (PEP).
DermaRep™ is disruptive and will become the benchmark in the wound healing market as it directly addresses the healthcare needs by providing a novel wound care product that is significantly more effective than current Standard of Care (SoC, relatively non-expensive silicon, foam and hydrocolloid dressings) and at least as effective as existing State of the Art (SoA) collagen-based dressings.
Champ scientifique
Programme(s)
Régime de financement
IA - Innovation actionCoordinateur
0275 OSLO
Norvège
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.